Table of Contents

• What is VE202?
• How VE202 Works
• Target Condition: Mild to Moderate Ulcerative Colitis
• Clinical Trial Details
• Eligibility Criteria
• Potential Benefits
• Safety Considerations

What is VE202?

VE202 is an innovative drug being studied for the treatment of mild to moderate ulcerative colitis. It is a capsule containing multiple strains of live bacteria, also known as a live biotherapeutic product. VE202 is currently undergoing a Phase 2 clinical trial to evaluate its effectiveness and safety in patients with ulcerative colitis.^[1]

How VE202 Works

VE202 contains a combination of carefully selected live bacterial strains. These bacteria are thought to help restore balance to the gut microbiome, which is the community of microorganisms living in our digestive system. In patients with ulcerative colitis, this balance is often disrupted. By introducing beneficial bacteria, VE202 aims to improve gut health and reduce inflammation associated with ulcerative colitis.^[1]

Target Condition: Mild to Moderate Ulcerative Colitis

Ulcerative colitis is a type of inflammatory bowel disease (IBD) that causes inflammation and ulcers in the lining of the large intestine (colon) and rectum. Symptoms can include diarrhea, abdominal pain, and rectal bleeding. The current study focuses on patients with mild to moderate ulcerative colitis, which means their symptoms are present but not severe enough to require hospitalization.^[1]

Clinical Trial Details

The ongoing clinical trial for VE202 is a Phase 2 study, which means it’s designed to further evaluate the drug’s effectiveness and safety. Here are some key details about the trial:

• It’s a randomized, double-blind, placebo-controlled study. This means that participants are randomly assigned to receive either VE202 or a placebo, and neither the participants nor the researchers know who is receiving which treatment.
• The treatment period lasts for 8 weeks.
• The main goal is to see if VE202 can improve the appearance of the colon lining when examined through a flexible sigmoidoscopy (a procedure that allows doctors to view the lower part of the colon) after 56 days of treatment.
• The study also aims to evaluate the safety of VE202.

These aspects of the trial design help ensure that the results are as unbiased and reliable as possible.^[1]

Eligibility Criteria

To participate in this clinical trial, patients must meet certain criteria. Some key eligibility requirements include:

• Age between 18 and 75 years
• Diagnosed with ulcerative colitis at least 3 months before the study
• Have active mild to moderate ulcerative colitis, as determined by specific medical criteria
• Have not previously received certain types of medications for ulcerative colitis, such as biologic agents or Janus kinase inhibitors
• If taking other medications for ulcerative colitis, the doses must have been stable for a certain period before the study

There are also several exclusion criteria, such as having other specific medical conditions or recent use of certain treatments that could interfere with the study results.^[1]

Potential Benefits

While the effectiveness of VE202 is still being studied, the potential benefits for patients with mild to moderate ulcerative colitis could include:

• Improvement in symptoms such as diarrhea, abdominal pain, and rectal bleeding
• Reduction in inflammation of the colon lining
• A new treatment option that works differently from existing medications
• Possible avoidance of more aggressive treatments if VE202 proves effective

It’s important to note that these potential benefits are still being investigated in the clinical trial.^[1]

Safety Considerations

As with any investigational treatment, the safety of VE202 is a primary concern in the clinical trial. The study is designed to carefully monitor for any side effects or adverse reactions. Some safety considerations include:

• The trial excludes patients with certain medical conditions or those using specific medications to minimize potential risks.
• Participants are closely monitored throughout the study period.
• The study specifically looks at the occurrence of serious adverse events and treatment-related adverse events.
• There are strict criteria for when a participant should discontinue the treatment for safety reasons.

It’s crucial to remember that VE202 is still an experimental treatment, and its full safety profile is not yet known. Patients considering participation in the clinical trial should discuss the potential risks and benefits with their healthcare provider.^[1]